Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses

Clinical studies include occurrences of rare variables, like genotypes, which due to their frequency and strength render their effects difficult to estimate from a dataset. Variables that influence the estimated value of a model-based parameter are termed covariates. It is often difficult to determine if such an effect is significant, since type I error can be inflated when the covariate is rare. Their presence may have either an insubstantial effect on the parameters of interest, hence are ignorable, or conversely they may be influential and therefore non-ignorable. In the case that these covariate effects cannot be estimated due to power and are non-ignorable, then these are considered nuisance, in that they have to be considered but due to type 1 error are of limited interest. This study assesses methods of handling nuisance covariate effects. The specific objectives include (1) calibrating the frequency of a covariate that is associated with type 1 error inflation, (2) calibrating its strength that renders it non-ignorable and (3) evaluating methods for handling these non-ignorable covariates in a nonlinear mixed effects model setting. Type 1 error was determined for the Wald test. Methods considered for handling the nuisance covariate effects were case deletion, Box-Cox transformation and inclusion of a specific fixed effects parameter. Non-ignorable nuisance covariates were found to be effectively handled through addition of a fixed effect parameter.

[1]  S. Duffull,et al.  What do we learn from repeated population analyses? , 2015, British journal of clinical pharmacology.

[2]  J. Guedj,et al.  Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach , 2013, BMC Medical Research Methodology.

[3]  J. Schellens,et al.  Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses , 2012, The AAPS Journal.

[4]  France Mentré,et al.  Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models , 2012, Biometrics.

[5]  S. Duffull,et al.  Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET? , 2011, Journal of clinical pharmacy and therapeutics.

[6]  Mats O. Karlsson,et al.  Semiparametric Distributions With Estimated Shape Parameters , 2009, Pharmaceutical Research.

[7]  Julie Bertrand,et al.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  Richard C. Brundage,et al.  Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  S. Tett,et al.  A Bayesian approach for population pharmacokinetic modelling of sirolimus. , 2006, British journal of clinical pharmacology.

[10]  Jakob Ribbing,et al.  Power, Selection Bias and Predictive Performance of the Population Pharmacokinetic Covariate Model , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  K G Kowalski,et al.  Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. , 2001, Statistics in medicine.

[12]  D. B. White,et al.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  Peter I D Lee,et al.  Design and Power of A Population Pharmacokinetic Study , 2004, Pharmaceutical Research.

[14]  S. Higuchi,et al.  Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study. , 2004, Drug metabolism and pharmacokinetics.

[15]  Jogarao V. S. Gobburu,et al.  Application of Resampling Techniques to Estimate Exact Significance Levels for Covariate Selection During Nonlinear Mixed Effects Model Building: Some Inferences , 2004, Pharmaceutical Research.